U.S. FDA approves first cord blood product

搜索关注在线英语听力室公众号：tingroom，领取免费英语资料大礼包。

　　HEMACORD is indicated for use in hematopoietic stem cell transplantation procedures in patients with disorders³ affecting the blood forming system. For example, cord blood transplants have been used to treat patients with certain blood cancers and some inherited metabolic⁴ and immune system disorders.

　　"The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders," said Karen Midthun, director of FDA's Center for Biologics Evaluation⁵ and Research, in a statement.

　　HEMACORD contains hematopoietic progenitor cells (HPCs) from human cord blood. Cord blood is one of three sources of HPCs used in transplants. The other two are bone marrow⁶ and peripheral⁷ blood. Once these HPCs are infused into patients, the cells migrate to the bone marrow where they divide and mature. When the mature cells move into the bloodstream they can partially⁸ or fully⁹ restore the number and function of many blood cells, including immune function.

分享到：